News & Events
February 7, 2024
Dr. Janet Woodcock: A Visionary Leader in Regulatory Science and the Inspirational Force behind the Creation of Critical Path InstituteIn her nearly four decades with the U.S. Food and Drug Administration, Dr. Janet Woodcock personally transformed the culture of the agency in ways that will be sustained and have an everlasting impact. She understood that for the next stage of FDA’s regulatory mission to be effectively achieved, it would need to be grounded on......
January 23, 2024
C-Path, CPP Share Manuscript That Redefines Parkinson’s DiseaseC-Path and its Critical Path for Parkinson’s Consortium are pleased to share a new manuscript that redefines Parkinson’s disease based on advances in the understanding of the underlying biology of disease. C-Path is honored to serve as a catalyst for bringing together diverse stakeholders from around the world to share promising results in new ways. It’s clear. The best......
October 24, 2023
Critical Path for Parkinson’s Welcomes New Co-chairs Pagano, GaetanoCritical Path for Parkinson’s mission is to serve as a leading international consortium convening diverse stakeholders to collectively advance data driven collaborative research aimed at accelerating drug development. The CPP co-director has a unique opportunity for broad visibility and to contribute to advancing regulatory science and encourage collaboration amongst all stakeholders. The benefits to......
September 20, 2023
The CPP Consortium Welcomes Biohaven as its Newest MemberThe Critical Path for Parkinson’s Consortium is excited to welcome Biohaven as its newest member. Biohaven is a biopharmaceutical company aimed at discovering and developing novel life-changing therapies for people living with neurological and neuropsychiatric diseases by collaborating with leaders in scientific discovery and medicine. CPP is excited to work with Biohaven as one of many new members from......
August 25, 2023
C-Path is pleased to welcome Acurex Biosciences as the newest member joining its Critical Path for Parkinson’s ConsortiumAcureX is a pharmaceutical company on a mission to stop major neurodegenerative diseases before they start, with an initial focus on Parkinson’s disease. To achieve this, AcureX leverages a first-in-class peripheral drug-responsive biomarker assays to molecularly define and segment patients in combination with novel disease-modifying therapeutics. AcureX is ushering in a new era of precision medicine......